



July-August 2023

	ш				
Arizona	Health (Care Cost	Contain	ment Syst	em

Age Changes

Inside this Edition
Age Changes1
Category of Service Codes2
Coverage Codes 3-4
Code Changes Code Additions5
Code Description Changes
Date Changes ICD-10 Codes8
Procedure Daily Maximum8-9
Medicare, TPL10
Modifiers 10-19
Place of Service20
Prior Authorization21
Provider Type22
Reference Screen23

Code	Description	Minimum Age	Maximum Age
90678	Respiratory Syncytial Virus Vaccine, Pref, Subunit, Bivalent,	60 Y	999 Y
91314	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2)	006 M	0132 M
91317	Coronavirus Vaccine 18	006 M	059 M
0121A	Administration Of Coronavirus Vaccine 13, Reserved	012 Y	999 Y
0141A	Administration Of Coronavirus Vaccine 15, Reserved	006 M	132 M
0142A	Administration Of Coronavirus Vaccine 15, Reserved	006 M	132 M
0144A	Immunization Administration by Intramuscular Injection of Severe	006 M	0132 M
0151A	Administration Of Coronavirus Vaccine 16, Reserved	006 M	0132 M
0171A	Administration Of Coronavirus Vaccine 18, Reserved	006 M	059 M
0172A	Administration Of Coronavirus Vaccine 18, Reserved	006 M	059 M
0173A	Administration Of Coronavirus Vaccine 18, Reserved	006 M	059 M
0174A	Administration Of Coronavirus Vaccine 18, Reserved	006 M	059 M
91317	Coronavirus Vaccine 18	006 M	059 M
D1120	Prophylaxis-Child	000 Y	020 Y
O09. 33	Suprvsn Of Preg W Insufficient Antenatal Care,	009 Y	064 Y
O30.043	Twin Pregnancy, Dichorionic/Diamniotic,	009 Y	064 Y
Z3A.29	29 Weeks Gestation of Pregnancy	009 Y	064 Y

Category of Service

The following Category of Service has been added to the CPT codes.

- 30100 (Biopsy of Lining of Nose) COS 02 (Surgery)
- 97755 (Evaluation for Assistive Technology, Each 15 Minutes) COS 06 (Physical Therapy)

Codes

The following codes listed have been added to the Reference Screens.

Codes	Description	Effective Begin Date
	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for	
90380	intramuscular use	06/30/2023
	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for	
90381	intramuscular use	06/30/2023
	Respiratory Syncytial Virus Vaccine, Pref, Recombinant, Subunit, Adjuvanted, For	
90679	Intramuscular Use	05/03/2023
J0174	Injection, Lecanemab-Irmb, 1 mg	07/01/2023

Coverage Codes

- Effective January 1, 2023, the CPT code 81416 (Test for Detecting Exome, Sequence Analysis, Each Comparator Exome) has **Coverage Code 01** Covered Service/Code Available).
- Effective August 1, 2023, the following codes have Coverage Code 04 (Not Covered Service/Code Not Available).

0001U	0002U	0003U	0007U	0009U
0019U	0021U	0025U	0030U	0032U
0033U	0039U	0050U	0051U	0053U
0055U	0058U	0059U	0061U	

• Effective April 18, 2023, the coverage code for the CPT codes listed has been changed to 04 (Not Covered Service/Code Not Available).

	CPT/HCPCS Codes						
0001A	0051A	0073A	0093A	91305			
0002A	0052A	0074A	0094A	91306			
0003A	0053A	0081A	0111A	91307			
0004A	0054A	0082A	0112A	91308			
0011A	0064A	0083A	0113A	91309			
0012A	0071A	0091A	91300	91311			
0013A	0072A	0092A	91301				

• Effective for the dates listed the following CPT/HCPCS codes now have **Coverage Code 04** (Not Covered Service/Code Not Available).

Code	Description	Effective Begin Date
0053U	Fish Analysis Of 4 Genes in Prostate Needle Biopsy Specimen	07/01/2023
0098U	Test For Detection of Respiratory Disease-Causing Organism Using Amplified Probe, 14 Target Organisms	07/01/2019
0099U	Test For Detection of Respiratory Disease-Causing Organism Using Amplified Probe	07/02/2019
0100U	Test For Detection of Respiratory Disease-Causing Organism Using Amplified Probe	07/03/2019
0143U	Measurement Of 120 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0144U	Measurement Of 160 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0145U	Measurement Of 65 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0146U	Measurement Of 80 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0147U	Measurement Of 85 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0148U	Measurement Of 100 Or More Drugs or Metabolites in Urine Specimen	07/01/2023
0149U	Measurement Of 60 or More Drugs or Metabolites in Urine Specimen	07/01/2023
0150U	Measurement Of 120 or More Drugs or Metabolites in Urine Specimen	07/01/2023
0247U	Quantitative Measurement of Insulin-Like Growth Factor-Binding Protein 4 And Sex Hormone-Binding Globulin (SHBG) In Maternal Serum by LC-MS/MS To Evaluate Risk of Premature Birth	10/01/2022
0362T	Behavior Identification Supporting Assessment for Patient Exhibiting Destructive Behavior, Each 15 Minutes of Technicians' Face-To-Face Time	07/01/2023
0373T	Adaptive Behavior Treatment with Protocol Modification for Patient Exhibiting Destructive Behavior, Each 15 Minutes of Technicians' Face-To-Face Time	07/01/2023
C9146	Injection, Mirvetuximab Soravtansine-Gynx, 1 mg	07/01/2023
C9147	Injection, Tremelimumab-ACTL, 1 mg	07/01/2023
C9148	Injection, Teclistamab-CQYV, 0.5 mg	07/01/2023

G0512	Rural Health Clinic or Federally Qualified Health Center (RHC/FQHC) Only, Psychiatric Collaborative Care Model (Psychiatric COCM), 60 Minutes or More of Clinical Staff Time for Psychiatric COCM Services Directed by An RHC or FQHC Practitioner (Physician, NP, PA, OR CNM) Behavioral Health Care Manager and Consultation with A Psychiatric Consultant, Per Calendar Month	06/01/2023
G2023	Specimen Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]), Any Specimen Source	05/12/2023
G2024	Specimen Collection for Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]) From an Individual In A SNF Or By A Laboratory On Behalf Of A HHA, Any Specimen Source	05/12/2023
J2370	Injection, Phenylephrine HCL, Up To 1 ml	07/01/2023
S0030	Injection, Metronidazole, 500 mg	07/01/2023
S0073	Injection, Aztreonam, 500 mg	07/01/2023
S0077	Injection, Clindamycin Phosphate, 300 mg	07/01/2023
U0003	Infectious Agent Detection by Nucleic Acid (DNA Or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]), Amplified Probe Technique, Making Use of High Throughput Technologies As Described By CMS-2020-01-R	05/12/2023
U0004	2019-Ncov Coronavirus, Sars-Cov-2/2019-Ncov (Covid-19), Any Technique, Multiple Types or Subtypes (Includes All Targets), Non-CDC, Making Use of High Throughput Technologies as Described by CMS-2020-01-R	05/12/2023
U0005	Infectious Agent Detection by Nucleic Acid (DNA Or RNA); Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [Covid-19]), Amplified Probe Technique, CDC Or Non-CDC, Making Use of High Throughput Technologies, Completed Within 2 Calendar Days from Date of Specimen Collection (List Separately in Addition To Either HCPCS Code U0003 Or U0004) As Described By CMS-2020-01-R2	05/12/2023

Code Changes

Code C9149

Effective June 30, 2023, the HCPCS code C9149 (Injection, Teplizumab-MZWM mcg) will be end dated.

Code H0019

Effective June 30, 2023, the HCPCS code H0019 (Behavioral health; long-term residential (nonmedical, nonacute care in a residential treatment program where stay is typically longer than 30 days), without room and board, per diem), has had the following data end dated.

Coverage Code 01 changed to 04 (Not Covered Service/Code Not Available)

Place of Service 14 (Group Home); and 99 (Other Unlisted Facility)

Prior Authorization 02 (PA Required for LTC Recipients)

Category of Service 47 (Mental Health Services)

Provider types 23 (Home Health Agency) and 73 (Out-Of-State Enc or 1 Time FFS Prov)

Modifiers 22, 52, 56, 76, 77, CR, HF, Q5, Q6, TF, TG, U7

Revenue Codes 0900, 0905, 0906, 0907, 0911, 0912, 0913, 0914, 0919

Code <u>H2033</u>

Effective June 1, 2023, the HCPCS code H2033 (Multisystemic Therapy for Juveniles, per 15 Minutes) has been end dated for the listed provider types. The code will only be added on PR055 (Exception Group).

A4 - LIC Indep Substance Abuse Couns (LISAC) BC - Board Certified Behavior Analyst

CN - Clinical Nurse Specialist IC - Integrated Clinics
08 - Md-Physician 18 - Physician's Assistant
19 - Registered Nurse Practitioner 23 - Home Health Agency
31 - DO-Physician Osteopath 77- -BH Outpatient Clinic

85 - Licensed Clinical Social Worker (LCSW) 86 - Licensed Marriage & Family Therapist LMFT

87 - Licensed Professional Counselor (LPC)

Code Additions

Effective April 1, 2023, the following items have been added to the HCPCS codes below:

Modifier SG (Ambulatory Surgical Center); Place of Service 24; Revenue code 0490 Provider Type 43

Code	Description
A2019	Kerecis Omega3 Marigen Shield, Per Square Centimeter
A2020	AC5 Advanced Wound System (AC5)
A2021	Neomatrix, Per Square Centimeter
Q5129	Injection, Bevacizumab-ADCD (Vegzelma), Biosimilar, 10 M

Code Description Changed

The following CPT/HCPCS codes have had their description changed.

Codes	Description
0022U	DNA and RNA targeted sequencing analysis of 1-23 genes associated with non-small cell lung cancer, reported as presence/absence of variants and associated therapies to consider
0044A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, booster dose
0124A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose
0134A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose
0144A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25mcg/0.25 mL dosage, booster dose
0154A	Intramuscular administration of single severe acute respiratory syndrome coronavirus 2 (COVID-19) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose
0164A	Intramuscular administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose
0173A	Administration of Coronavirus Vaccine 18, Reserved
0174A	Administration of Coronavirus Vaccine 18, Reserved
0356U	Evaluation of 17 DNA biomarkers reported as a risk score for cancer recurrence
0357U	Artificial intelligence (AI)-enabled evaluation of 142 pairs of glycopeptide and product fragments in plasma to determine benefit from immunotherapy agents for skin cancer
0358U	Enzyme immunoassay analysis of beta-amyloid fragments in cerebral spinal fluid to evaluate mild mental impairment
0359U	Phase separation and immunoassay evaluation of prostate-specific antigen (PSA) in plasma to evaluate risk of prostate cancer
0360U	Enzyme-linked immunosorbent assay of autoantibodies in plasma to evaluate risk of malignancy in lung cancer
0361U	Digital immunoassay in plasma for neurofilament light chain
0362U	Gene-expression profilingenrichment RNA sequencing of 82 content genes and 10 housekeeping genes reported as one of three molecular subtypes in papillary thyroid cancer
0363U	Gene-expression profiling of 5 genes in urine reported as a risk score for having urothelial carcinoma
0364U	Genomic sequence testing for presence or absence of cancer cells after treatment in leukemia or lymphoma
0365U	Test for 10 protein biomarkers for bladder cancer
0366U	Test for 10 protein biomarkers for recurrent bladder cancer
0367U	Test for 10 protein biomarkers for rapid recurrent, recurrent, or persistent bladder cancer after bladder surgery to remove a tumor
0368U	Test for risk of colorectal cancer

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment		
1931 Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal organism 1932 Test for genitourinary pathogen antibiotic-resistance genes 1933 Test for 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes associated with respiratory infection 1934 Test for 12 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic- 1935 Test for proteins to determine risk for ovarian cancer 1935 Test for proteins to determine risk for ovarian cancer 1937 Test of dipoprotein profile in cardiovascular disease 1937 Test of lipoprotein profile in cardiovascular disease 1937 Test of proteins for solid organ cancer 1938 Test for RFC1 (replication factor C subunit 1) in neurological conditions 1939 Genomic testing for solid organ cancer 1938 Test for adverse drug reactions and drug response 1938 Test for monitoring maple syrup urine disease 1938 Test for monitoring hyperphenylalaninemia 1938 Test for monitoring hyperphenylalaninemia 1938 Test for monitoring tyrosinemia type I 1938 Test for for risk of Barrett's esophagus progression to esophageal cancer 1938 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 m. dosage, trins-sucrose formulation, for intramuscular use 1931 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.2 m. dosage, for intramuscular use 1933 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.2 m. dosage, for intramuscular use 1934 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.2 m. dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 1934 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 m. dosage, diluent reconstitu	0369U	Test for 31 stomach and intestinal pathogens and identification of 21 antibiotic resistant genes
19372U Test for genitourinary pathogen antibiotic-resistance genes 19373U Test for genitourinary pathogen antibiotic-resistance genes associated with respiratory infection 19473U Test for 12 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic- 19573U Test for proteins to determine risk for ovarian cancer 19575U Test for proteins to determine risk for ovarian cancer 19575U Test for proteins to determine risk for ovarian cancer 19575U Test for lipoprotein profile in cardiovascular disease 19575U Test of lipoprotein profile in cardiovascular disease 19575U Test for RFC1 (replication factor C subunit 1) in neurological conditions 19575U Genomic testing for solid organ cancer 19575U Test for adverse drug reactions and drug response 19585U Test for monitoring maple syrup urine disease 19585U Test for monitoring maple syrup urine disease 19585U Test for monitoring tyrosinemia type I 19585U Test for predictive risk of progression of high-stage kidney disease 19585U Testing for risk of developing diabetic kidney disease 19585U Testing for risk of developing diabetic kidney disease 19585U Testing for risk of developing diabetic kidney disease 19585U Testing for risk of Barrett's esophagus progression to esophageal cancer 19595U Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, for intramuscular use 19595U Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use 19505U Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use 19505U Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use 19505U Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine	0370U	Test for 34 surgical wound microorganisms and identification of 21 antibiotic resistant genes
Test for 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes associated with respiratory infection Test for 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic-resistance genes Test for proteins to determine risk for ovarian cancer Test to determine potential risk of prostate cancer spread and mortality Test of lipoprotein profile in cardiovascular disease Test for RFC1 (replication factor C subunit 1) in neurological conditions Test for adverse drug reactions and drug response Test for adverse drug reactions and drug response Test for monitoring maple syrup urine disease Test for monitoring maple syrup urine disease Test for monitoring tyrosinemia type I Test for predictive risk of progression of high-stage kidney disease Test for predictive risk of progression of high-stage kidney disease Testing for risk of developing diabetic kidney disease Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 20 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative fr	0371U	Test for 16 genitourinary bacterial organisms and 1 genitourinary fungal organism
Test for 21 bacterial and fungal genitourinary pathogens and identification of 21 associated antibiotic- resistance genes 375U Test for proteins to determine risk for ovarian cancer 376U Test to determine potential risk of prostate cancer spread and mortality 377U Test of lipoprotein profile in cardiovascular disease 378U Test for RFC1 (replication factor C subunit 1) in neurological conditions 379U Genomic testing for solid organ cancer 380U Test for adverse drug reactions and drug response 381U Test for monitoring maple syrup urine disease 382U Test for monitoring hyperphenylalaninemia 383U Test for monitoring hyperphenylalaninemia 383U Test for predictive risk of progression of high-stage kidney disease 385U Testing for risk of developing diabetic kidney disease 385U Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent of the month of the preparatory procedures, administration, and dressings, per tre	0372U	Test for genitourinary pathogen antibiotic-resistance genes
resistance genes 375U Test for proteins to determine risk for ovarian cancer 376U Test to determine potential risk of prostate cancer spread and mortality 377U Test of lipoprotein profile in cardiovascular disease 378U Test for RFC1 (replication factor C subunit 1) in neurological conditions 379U Genomic testing for solid organ cancer 380U Test for adverse drug reactions and drug response 381U Test for monitoring maple syrup urine disease 382U Test for monitoring hyperphenylalaninemia 383U Test for monitoring tyrosinemia type I 384U Test for predictive risk of progression of high-stage kidney disease 385U Testing for risk of developing diabetic kidney disease 385U Testing for risk of Barrett's esophagus progression to esophageal cancer 386U Testing for risk of Barrett's esophagus progression to esophageal cancer 387U Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, fris-sucrose formulation, for intramuscular use 3880 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 3890 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 3891 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 3892 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 3893 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 3894 Severe acute respiratory syndrome c	0373U	Test for 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes associated with respiratory infection
Test for proteins to determine risk for ovarian cancer Test to determine potential risk of prostate cancer spread and mortality Test of lipoprotein profile in cardiovascular disease Test for RFC1 (replication factor C subunit 1) in neurological conditions Garyou Genomic testing for solid organ cancer Test for adverse drug reactions and drug response Test for monitoring maple syrup urine disease Test for monitoring maple syrup urine disease Test for monitoring tyrosinemia type I Test for monitoring tyrosinemia type I Test for predictive risk of progression of high-stage kidney disease Testing for risk of developing diabetic kidney disease Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acu	0374U	
Test to determine potential risk of prostate cancer spread and mortality Test of lipoprotein profile in cardiovascular disease Test for RFC1 (replication factor C subunit 1) in neurological conditions Genomic testing for solid organ cancer Test for adverse drug reactions and drug response Test for monitoring maple syrup urine disease Test for monitoring maple syrup urine disease Test for monitoring tyrosinemia type I Test for predictive risk of progression of high-stage kidney disease Testing for risk of developing diabetic kidney disease Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vacc	-	
Test of lipoprotein profile in cardiovascular disease 3780 Test for RFC1 (replication factor C subunit 1) in neurological conditions 3790 Genomic testing for solid organ cancer 3800 Test for adverse drug reactions and drug response 3810 Test for monitoring maple syrup urine disease 3820 Test for monitoring hyperphenylalaninemia 3830 Test for monitoring tyrosinemia type I 3840 Test for predictive risk of progression of high-stage kidney disease 3850 Testing for risk of developing diabetic kidney disease 3860 Testing for risk of Barrett's esophagus progression to esophageal cancer 3860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 3860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 3860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 3860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 3860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 3870 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 3880 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 3890 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-	0376U	·
Test for RPC1 (replication factor C subunit 1) in neurological conditions 379U Genomic testing for solid organ cancer 380U Test for adverse drug reactions and drug response 381U Test for monitoring maple syrup urine disease 382U Test for monitoring hyperphenylalaninemia 383U Test for monitoring tyrosinemia type I 384U Test for predictive risk of progression of high-stage kidney disease 385U Testing for risk of developing diabetic kidney disease 385U Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 20 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, prese	0377U	
O379U Genomic testing for solid organ cancer O380U Test for adverse drug reactions and drug response O381U Test for monitoring maple syrup urine disease O382U Test for monitoring hyperphenylalaninemia O383U Test for monitoring tyrosinemia type I O384U Test for predictive risk of progression of high-stage kidney disease O385U Testing for risk of developing diabetic kidney disease O386U Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for d	0378U	
19380 Test for adverse drug reactions and drug response 193810 Test for monitoring maple syrup urine disease 193820 Test for monitoring hyperphenylalaninemia 193830 Test for monitoring tyrosinemia type I 193840 Test for predictive risk of progression of high-stage kidney disease 193850 Testing for risk of developing diabetic kidney disease 193860 Testing for risk of Barrett's esophagus progression to esophageal cancer 193860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 ml dosage, tris-sucrose formulation, for intramuscular use 19331 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 19334 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 19335 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 19336 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use 19336 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 19337 Proservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 19338 Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment 19337 Autologous platelet rich plasma (PRP) or other blood derived product for diabet	-	
193810 Test for monitoring maple syrup urine disease 193820 Test for monitoring hyperphenylalaninemia 193830 Test for monitoring tyrosinemia type I 193840 Test for predictive risk of progression of high-stage kidney disease 193850 Testing for risk of developing diabetic kidney disease 193860 Testing for risk of Barrett's esophagus progression to esophageal cancer 193860 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use 193131 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use 19314 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use 19315 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 19316 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use 19316 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use 19317 Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment 19318 Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all	0380U	
Test for monitoring tyrosinemia type I 388U Test for predictive risk of progression of high-stage kidney disease 385U Testing for risk of developing diabetic kidney disease 386U Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixi	0381U	
Test for predictive risk of progression of high-stage kidney disease Testing for risk of developing diabetic kidney disease Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	0382U	
Testing for risk of developing diabetic kidney disease Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	0383U	Test for monitoring tyrosinemia type I
Testing for risk of Barrett's esophagus progression to esophageal cancer Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 3 mcg/0.2 mL dosage, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	0384U	Test for predictive risk of progression of high-stage kidney disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	0385U	Testing for risk of developing diabetic kidney disease
91312 preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	0386U	Testing for risk of Barrett's esophagus progression to esophageal cancer
91313 preservative free, 50 mcg/0.5 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91312	
91314 preservative free, 25 mcg/0.25 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91313	
91315 preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91314	
91316 preservative free, 10 mcg/0.2 mL dosage, for intramuscular use Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
91317 preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use Autologous platelet rich plasma or other blood derived product for non-diabetic chronic wounds/ulcers, including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91316	
including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures, administration, and dressings, per treatment Autologous platelet rich plasma (PRP) or other blood derived product for diabetic chronic wounds/ulcers, using an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	91317	
an FDA cleared device for this indication, (includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment	G0460	including as applicable phlebotomy, centrifugation or mixing, and all other preparatory procedures,
J2426 Injection, paliperidone palmitate extended release (invega sustenna), 1 mg	G0465	
	J2426	Injection, paliperidone palmitate extended release (invega sustenna), 1 mg

Date Change

The CPT code 88361 (Microscopic Genetic Analysis of Tumor, Using Computer-Assisted Technology) end date has been changed to 99/99/9999.

ICD-10 Codes

Effective October 1, 2022, the following ICD-10 codes have been added to the Reference Screen RF724.

F10.90 - Alcohol Use, Unspecified, Uncomplicated

F1091 - Alcohol Use, Unspecified, In Remission

The Age Change on RF223 P74.31 (Hyperkalemia of Newborn) minimum age 000 Y maximum age 999 Y

Procedure Daily Maximum

Code	Limits								
J0120	1	J1260	2	J2501	2	J7177	10500	J7639	3
J0122	300	J1265	20	J2506	12	J7178	7700	J7644	3
J0171	20	J1270	8	J2510	4	J7179	7500	J7674	100
J0202	12	J1290	30	J2515	1	J7180	6000	J7682	2
J0207	4	J1322	150	J2540	75	J7183	7500	J7686	1
J0219	750	J1324	108	J2550	3	J7185	4000	J8510	5
J0220	1	J1327	1	J2562	48	J7188	22000	J8540	48
J0221	250	J1435	1	J2675	1	J7196	175	J8650	6
J0222	300	J1442	1500	J2704	80	J7201	9000	J8705	22
J0282	5	J1444	272	J2710	2	J7202	11550	J9015	1
J0285	5	J1458	100	J2770	6	J7203	12000	J9023	140
J0400	39	J1555	480	J2779	20	J7204	19500	J9027	100
J0515	3	J1572	180	J2787	2	J7205	9750	J9039	210
J0558	24	J1575	650	J2790	1	J7207	22500	J9043	60
J0561	24	J1630	5	J2791	50	J7210	22000	J9045	22
J0594	320	J1650	30	J2794	100	J7211	22000	J9060	24
J0595	8	J1652	20	J2795	200	J7212	90000	J9070	55
J0597	250	J1670	1	J2805	3	J7312	14	J9120	5

		14720	25	12040	460	17242	20	104.44	400
J0598	100	J1729	25	J2840	160	J7313	38	J9144	180
J0690	12	J1741	8	J2850	16	J7328	336	J9160	7
J0692	12	J1742	2	J2860	170	J7340	1	J9171	240
J0697	4	J1743	66	J2941	8	J7500	15	J9178	150
J0712	120	J1744	30	J3030	1	J7507	40	J9190	20
J0716	4	J1750	45	J3060	760	J7508	300	J9207	90
J0742	500	J1790	2	J3095	150	J7511	9	J9213	12
J0744	6	J1815	8	J3246	1	J7520	40	J9246	300
J0840	6	J1885	8	J3285	1	J7605	2	J9264	700
J0841	20	J1931	377	J3285	400	J7606	2	J9266	2
J0882	300	J1955	11	J3370	12	J7608	3	J9269	200
J0883	1125	J2170	8	J3385	80	J7611	10	J9299	480
J0884	1125	J2175	4	J3410	8	J7612	10	J9302	200
J0885	60	J2260	4	J3415	6	J7613	10	J9303	90
J1097	4	J2270	9	J3472	2	J7614	10	J9307	80
J1162	1	J2300	4	J7100	2	J7620	6	J9308	280
J1200	8	J2310	4	J7110	2	J7626	2	J9356	60
J1250	2	J2405	64	J7121	4	J7631	4	J9360	40
								J9400	500

The following codes have had the Procedure Daily Maximum changed.

Code	Description	Procedure Daily Maximum
26590	Repair Of Enlarged Finger	2
28005	Incision Of Foot Bone	3
64421	Injection Of Anesthetic Agent and/or Steroid into Multiply Rib	4
97802	Therapy Procedure for Nutrition Management, Each 15 Minutes	12
	Aminolevulinic Acid HCl for Topical Administration, 20%, Single Unit Dosage	
J7308	Form (354 mg)	3

Medicare and TPL Indicators

The Medicare and TPL indicators on the Reference Screens has been changed to "N" for the CPT code 3044F (Most Recent Hemoglobin A1C (HBA1C) level less than 7.0).

Modifiers

Effective December 31, 2022, the modifier 51 (Multiple Procedures) has been end dated for CPT code 64421 (Injection of Anesthetic Agent and/or Steroid into Multiple Rib Nerves for Regional Nerve Block).

Effective January 1, 2023, the modifier AB (Audiology Service Furnished Personally) has been added to the following CPT codes.

92550	92552	92553	92555	92556	92557
92562	92563	92565	92567	92568	92570
92571	92572	92575	92576	92577	92579
92582	92583	92584	92587	92588	92601
92602	92603	92604	92620	92621	92625
92626	92627	92640	92652	92653	

Effective July 1, 2023, the modifier UB (Monthly Serv Per Member/(BH) MHBG Funded) has been added to the following CPT/HCPCS codes.

	Codes							
0359T	80342	80374	86701	93000	98968	99349	A0170	S5151
36415	80343	80375	86702	93005	99091	99350	A0180	S9484
80048	80344	80376	86703	93010	99199	99354	A0190	S9485
80050	80345	80377	87390	93040	99201	99355	A0200	T1002
80051	80346	81001	87391	93041	99202	99358	A0210	T1002
80053	80347	81002	90785	93042	99203	99359	H0002	T1003
80076	80348	81003	90791	93268	99204	99441	H0004	T1016
80299	80349	81005	90792	95819	99205	99442	H0031	T1019

80305	80350	81025	90832	96110	99211	99443	H0036	T1020
80303	80330	81023	90832	90110	99211	33443	110030	11020
80306	80351	81050	90833	96116	99212	0360T	H0037	T2005
80307	80352	82075	90834	96121	99213	0361T	H0038	T2007
80320	80353	82382	90836	96130	99214	0362T	H2010	T2049
80321	80354	82465	90837	96131	99215	0363T	H2011	
80323	80356	82530	90838	96133	99241	0364T	H2012	
80324	80357	82533	90839	96372	99242	0365T	H2014	
80325	80358	82542	90840	97151	99243	0366T	H2015	
80326	80359	82565	90845	97152	99244	0367T	H2016	
80327	80360	82570	90846	97153	99245	0368T	H2017	
80328	80361	82575	90847	97154	99281	0369T	H2019	
80331	80362	82607	90849	97155	99282	0370T	H2020	
80332	80363	82746	90853	97156	99283	0371T	H2025	
80333	80364	83789	90863	97157	99284	0372T	H2026	
80334	80365	83992	90867	97158	99285	0373T	H2027	
80335	80367	84311	90868	97802	99341	0374T	H2033	
80336								

Effective June 30, 2023, the modifier FQ (The Service Was Furnished Using Audio-On) has been end dated for the following codes.

99202	99211	99417
99203	99212	99288
99204	99213	99358
99205	99214	99359
99211	99215	

Effective July 1, 2023, the following modifiers have been added to the codes listed.

Code	Modifier	Code	Modifier
0791T	51	0802T	51 & 62
0793T	51	0803T	51; & 62
0795T	51 & 62	0804T	TC; 26; 51
0796T	51 & 62	0805T	51; 62; 66
0797T	51 & 62	0806T	51; 62; 66
0798T	51	0807T	TC; 26; 51
0799T	51	0808T	TC; 26; 51
0800T	51	0809T	50; 51, 62
0801T	51 & 62	0810T	50; 51, 62

50 Bilateral Procedure (Pay 50%)

51 Multiple Procedures

Two Surgeons/Different Skills

66 Surgical Team

Effective July 1, 2023, the modifiers LT (Identifies Left Side) & RT (Identifies Right Side) have been added to codes below.

Codes	Codes Codes		Codes
V2219	V2399	V5040	V5172
V2220	V2610	V5050	V5181
V2299	V2762	V5060	V5190
V2319	V2786	V5095	
V2320	V5030	V5171	

The modifiers LT (Identifies Left Side) & RT (Identifies Right Side) have been end dated as of June 30, 2023

V5248	V5249	V5259	V5258
V5250	V5251	V5261	V5260
V5252	V5253	V6263	V5262

Effective for the dates listed the following modifiers have been added to the Reference Screen.

Code	Description	Modifiers	Effective Begin Date
	Injection Of Chemical for Paralysis of		
	Nerve Muscles on Arm or Leg, 1-4	58 - Staged/Related Proc Same Post-OP	
64643	Muscles, Each Additional Extremity	Period 8	01/01/2023
	Electrical Stimulation for Guidance with		
	Injection of Chemical for Paralysis of	58 - Staged/Related Proc Same Post-OP	
95873	Nerve Muscle	Period	01/01/2023
C9148	Injection, Teclistamab-CQYV, 0.5 mg	JG - Drug or Biological Acquired With 340B Dr	04/01/2023
		JW - Drug Amt Discarded/Not Admin to Any	
C9148	Injection, Teclistamab-CQYV, 0.5 mg	Pati	04/01/2023
C9148	Injection, Teclistamab-CQYV, 0.5 mg	TB - Drug or Biological Acquired With 340B Dr	04/01/2023
J9380	Injection, Teclistamab-Cqyv, 0.5 mg	JG - Drug or Biological Acquired With 340B Dr	07/01/2023
		JW - Drug Amt Discarded/Not Admin to Any	
J9380	Injection, Teclistamab-Cqyv, 0.5 mg	Pati	07/01/2023
J9380	Injection, Teclistamab-Cqyv, 0.5 mg	TB - Drug or Biological Acquired With 340B Dr	07/01/2023
	Test To Assess Hearing Using 2 Syllable		
92572	Words	AB - Audiology Service Furnished Personally	01/01/2023

Effective June 30, 2023, the modifier FQ (The Service Was Furnished Using Audio-On) has been **end dated** for 99497 (Advance Care Planning, first 30 Minutes) and 99498 (Advance Care Planning, Each Additional 30 Minutes).

Effective January 1, 2023, the following modifier (UE - Used Durable Medical Equipment) has been added to the HCPCS codes listed.

A8000	A8001	A8002	A8003	A8004
AOUUU	AOUUI	HOUUZ	A6003	A0004

Effective January 1, 2023, the following modifiers (RA - Replacement DME/Orthotic/Prosthetic) and RB (Replace Part of DME/Orthotic/Prosthetics) has been added to the HCPCS codes listed

	Codes						
Q0480	Q0486	Q0493	Q0500				
Q0481	Q0487	Q0494	Q0501				
Q0482	Q0489	Q0495	Q0502				
Q0483	Q0490	Q0496	Q0503				
Q0484	Q0491	Q0497	Q0504				
Q0485	Q0492	Q0499	Q0506				

Effective January 1, 2023, the following modifiers have been added to the HCPCS codes listed

Code	Modifiers
J7030	Drug Amt Discarded/Not Admin to Any Pati
J7030	JZ - Zero Drug Amount Discarded/Not Administered
K1006	NR - New When Rented/AMB SNF to Residence
K1006	NU - New Equipment
K1006	RA - Replacement DME/Orthotic/Prosthetic
K1006	RB - Replace Part of DME/Orthotic/Prosthetic
K1006	UUE - Used Durable Medical Equipment
K1025	NR - New When Rented/AMB SNF to Residence
K1025	NU - New Equipment
K1025	RA - Replacement DME/Orthotic/Prosthetic
K1025	RB - Replace Part of DME/Orthotic/Prosthetic
K1025	UE - Used Durable Medical Equipment
Q0498	RB - Replace Part of DME/Orthotic/Prosthetic

• Effective for the dates listed the following modifiers have been added to the codes.

Code	Description	Modifier	Begin Date
00170		78 - Return to O.R. For Related Proc	04 /04 /0000
00170	Anesthesia For Other Procedure on Mouth	Post-Op	01/01/2023
40205	Removal Or Destruction of Cysts or Growths Of	78 - Return to O.R. for related	04 /04 /2022
49205	Abdominal Cavity, More Than 10.0 Cm	procedure Post-OP	01/01/2023
49591	Initial Repair of Sliding Hernia of Abdomen, Less Than 3 Cm In Length	AS - PA SVCS for Assistant	01/01/2023
49591	Initial Repair of Sliding Hernia Of Abdomen, Less Than 3 Cm In Length	80 - Assistant Surgeon	01/01/2023
49591	Initial Repair of Sliding Hernia Of Abdomen, Less Than 3 Cm In Length	81 - Minimum Assistant Surgeon	01/01/2023
49591	Initial Repair of Sliding Hernia Of Abdomen, Less Than 3 Cm In Length	82 - Assist Surg/Qual Resident	01/01/2023
93650	Destruction of Heart Conduction Tissue To Create Heart	51 - Multiple Procedures	07/01/2022
96138	Administration Of Psychological or Neuropsychological Test by Technician, first 30 minutes	HO - Master's Degree Level	08/01/2022
96138	Administration Of Psychological or Neuropsychological Test by Technician, first 30 minutes	HP - Doctoral Level	08/01/2022
96139	Administration Of Psychological or Neuropsychological Test by Technician, each additional 30 minutes	HO - Master's Degree Level	08/01/2022
96139	Administration Of Psychological or Neuropsychological Test by Technician, each additional 30 minutes	HP - Doctoral Level	08/01/2022
99213	Established Patient Office or Other Outpatient Visit, 20-29 Minutes	FS - Split (Or Shared) Evaluation and Management	01/01/2023
99214	Established Patient Office or Other Outpatient Visit, 30-39 Minutes	FS - Split (Or Shared) Evaluation and Management	01/01/2023
99215	Established Patient Office or Other Outpatient Visit, 40-54 Minutes	FS - Split (Or Shared) Evaluation and Management	01/01/2023
A4224	Supplies For Maintenance of Insulin Infusion Catheter, Per Week	KX - Requirements Specified in The Medical Po	03/01/2023
A4225	Supplies For External Insulin Infusion Pump, Syringe Type Cartridge, Sterile, Each	KX - Requirements Specified in The Medical Po	03/01/2023

		ı	
	Wheelchair Accessory, Headrest, Cushioned, Any		
E0955	Type, Including Fixed Mounting Hardware, Each	DMEPOS Comp Bid 3	01/01/2023
E1007	Wheelchair Accessory, Power Seating System, Combination Tilt and Recline, With Mechanical Shear Reduction	KU - DMEPOS Item Subject to DMEPOS Comp Bid 3	01/01/2023
E1028	Wheelchair Accessory, Manual Swingaway, Retractable or Removable Mounting Hardware for Joystick, Other Control Interface, or Positioning Accessory	KU - DMEPOS Item Subject to DMEPOS Comp Bid 3	01/01/2023
E2361	Power Wheelchair Accessory, 22NF Sealed Lead Acid Battery, Each, (e.g., gel cell, absorbed glass mat)	KU - DMEPOS Item Subject to DMEPOS Comp Bid 3	01/01/2023
E2620	Positioning Wheelchair Back Cushion, Planar Back with Lateral Supports, Width Less Than 22 Inches, Any Height, Including Any Type Mounting Hardware	KU - DMEPOS Item Subject to DMEPOS Comp Bid 3	01/01/2023
J0129	Injection, Abatacept, 10 Mg (Code May Be Used for Medicare When Drug Administered Under the Direct Supervision of a Physician, Not for Use When Drug Is Self-Administered)	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J0180	Injection, Agalsidase Beta, 1 mg	JZ - Zero Drug Amount Discard	01/01/2023
J0485	Injection, Belatacept, 1 mg	JA - Administered Intravenously	07/01/2022
J0490	Injection, Belimumab, 10 g	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J0491	Injection, Anifrolumab-FNIA, 1 mg	JW - Drug Amount Discarded/ Not Admin to Any Patient	10/01/2022
J0565	Injection, Bezlotoxumab, 10 mg	JW - Drug Amt Discarded/Not Admin to Any Pati	03/01/2022
J0585	Injection, Onabotulinumtoxina, 1 Unit	JZ - Zero Drug Amount Discard/Not Administered	01/01/2023
J0585	Injection, Onabotulinumtoxina, 1 unit	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
J0586	Injection, Abobotulinumtoxina, 5 Units	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
J0587	Injection, Rimabotulinumtoxinb, 100 Units	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
J0878	Injection, Daptomycin, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
			-

Injection, Luspatercept-Aamt, 0.25 mg	TB - Drug or Biological Acquired with 340B Dr	07/01/2022
Injection, Dexamethasone Sodium Phosphate, 1 mg	JW - Drug Amt Discarded/Not Admin to Any Patient	07/01/2023
Injection, Dexamethasone Sodium Phosphate, 1 mg	JZ - Zero Drug Amount Discard	07/01/2023
Injection, Diphenhydramine HCL, Up To 50 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Injection, Ferric Derisomaltose, 10 mg	TB - Drug or Biological Acquired With 340B Dr	01/01/2023
Injection, Ferric Derisomaltose, 10 mg	JG - Drug or Biological Acquired With 340B Dr	01/01/2023
Injection, Fosaprepitant, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg	KP - First Drug of a Multiple Drug Unit Dose	01/01/2023
Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg	KQ - Second or Subsequent Drug of a Multi Dose	01/01/2023
Injection, Immune Globulin, (Gammagard Liquid), Non-Lyophilized,	TB - Drug or Biological Acquired with 340B Dr	07/01/2022
Injection, Heparin Sodium, (Heparin Lock Flush), Per 10	JW - Drug Amt Discarded/Not Admin to Any Patient	07/01/2022
Injection, Ketorolac Tromethamine, Per 15 mg	JZ - Zero Drug Amount Discard	07/01/2023
Injection, Mepolizumab, 1 mg	JW - Drug Amt Discarded/Not Admin to Any Patient	07/01/2023
Injection, Mepolizumab, 1 mg	JZ - Zero Drug Amount Discard	07/01/2023
Injection, Natalizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Injection, Ocrelizumab, 1 mg	JW - Drug Amount Discarded/ Not Admin to Any Patient	10/01/2022
Injection, Ocrelizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Injection, Ondansetron Hydrochloride, Per 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Injection, Ondansetron Hydrochloride, Per 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
	Injection, Dexamethasone Sodium Phosphate, 1 mg Injection, Dexamethasone Sodium Phosphate, 1 mg Injection, Diphenhydramine HCL, Up To 50 mg Injection, Ferric Derisomaltose, 10 mg Injection, Ferric Derisomaltose, 10 mg Injection, Fosaprepitant, 1 mg Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg Injection, Immune Globulin, (Gammagard Liquid), Non-Lyophilized, Injection, Heparin Sodium, (Heparin Lock Flush), Per 10 Injection, Ketorolac Tromethamine, Per 15 mg Injection, Mepolizumab, 1 mg Injection, Natalizumab, 1 mg Injection, Ocrelizumab, 1 mg Injection, Ocrelizumab, 1 mg Injection, Ocrelizumab, 1 mg	Injection, Luspatercept-Aamt, 0.25 mg Injection, Dexamethasone Sodium Phosphate, 1 mg Injection, Dexamethasone Sodium Phosphate, 1 mg Iz - Zero Drug Amount Discarded/Not Admin to Any Patient Iz - Zero Drug Amount Discard Injection, Diphenhydramine HCL, Up To 50 mg Ig - Drug or Biological Acquired With 340B Dr Ig - Drug or Biological Acquired With 340B Dr Iz - Zero Drug Amount Discarded/Not Administered Injection, Ferric Derisomaltose, 10 mg Iz - Zero Drug Amount Discarded/Not Administered Injection, Fosaprepitant, 1 mg Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg Injection, Immune Globulin (Privigen), Intravenous, Non-Lyophilized (e.g., liquid), 500 mg Injection, Immune Globulin, (Gammagard Liquid), Non-Lyophilized, Injection, Heparin Sodium, (Heparin Lock Flush), Per 10 Injection, Ketorolac Tromethamine, Per 15 mg Iz - Zero Drug Amount Discarded/Not Admin to Any Patient Injection, Mepolizumab, 1 mg Iz - Zero Drug Amount Discard Injection, Natalizumab, 1 mg Iz - Zero Drug Amount Discarded/Not Admin to Any Patient Injection, Ocrelizumab, 1 mg Iz - Zero Drug Amount Discarded/Not Admin to Any Patient Injection, Ocrelizumab, 1 mg Injection, Ocrelizumab, 1 mg Iz - Zero Drug Amount Discarded/Not Administered Iz - Zero Drug Amount

J2469	Injection, Palonosetron HCL, 25 mcg	JZ - Zero Drug Amount Discard	07/01/2023
J2506	Injection, Pegfilgrastim, Excludes Biosimilar, 0.5 mg	JG - Drug or Biological Acquired With 340B Dr	07/01/2022
J2550	Injection, Promethazine HCL, Up To 50 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
J2930	Injection, Methylprednisolone Sodium Succinate, Up To 125 mg	JZ - Zero Drug Amount Discard	07/01/2023
J3101	Injection, Tenecteplase, 1 mg	JW - Drug Amt Discarded/Not Admin to Any Patient	01/01/2023
J3101	Injection, Tenecteplase, 1 mg	JZ - Zero Drug Amount Discard	01/01/2023
J3380	Injection, Vedolizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J7030	Infusion, Normal Saline Solution, 1000 cc	JW - Drug Amt Discarded/Not Admin to Any Pati	01/01/2023
J7030	Infusion, Normal Saline Solution, 1000 cc	JZ - Zero Drug Amount Discard	01/01/2023
J9000	Injection, Doxorubicin Hydrochloride, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
J9035	Injection, Bevacizumab, 10 mg	JZ - Zero Drug Amount Discard	07/01/2023
J9199	Injection, Cemiplimab-RWLC, 1 mg	JG - Drug or Biological Acquired With 340B Dr	01/01/2023
J9271	Injection, Pembrolizumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J9305	Injection, Pemetrexed, Not Otherwise Specified, 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J9306	Injection, Pertuzumab, 1 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
J9394	Injection, Fulvestrant (Fresenius KABI) Not Therapeutically Equivalent to J9395, 25 mg	JG - Drug or Biological Biological Acquired with any 340 Drug	01/01/2023
J9394	Injection, Fulvestrant (Fresenius KABI) Not Therapeutically Equivalent to J9395, 25 mg	JW - Drug Amount Discarded/ Not Administered to any Patient	01/01/2023
J9394	Injection, Fulvestrant (Fresenius KABI) Not Therapeutically Equivalent to J9395, 25 mg	TB - Drug or Biological Acquired with 340B Drug	01/01/2023
K0739	Repair Or Nonroutine Service for Durable Medical Equipment Other Than Oxygen Equipment Requiring the Skill of A Technician, Labor Component, Per 15 Minutes	RB - Replace Part Of DME/Orthotic/Prosthetic	01/01/2023

K0861	Power Wheelchair, GRP 3 STD. Multi Power OPT. Sling'SOL	KU - DMEPOS Item Subject to DMEPOS Comp Bid 3	01/01/2023
P9047	Infusion, Albumin (Human), 25%, 50 ml	JW - Drug Amt Discarded/No	01/01/2023
P9047	Infusion, Albumin (Human), 25%, 50 ml	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Q2056	Ciltacabtagene Autoleucel, Up To 100 million Autologous B-Cell Maturation	TB - Drug Or Biological Acquired With 340B Dr	10/01/2022
Q2056	Ciltacabtagene Autoleucel, Up To 100 million Autologous B-Cell Maturation	JG - Drug or Biological Acquired with 340B Dr	10/01/2022
Q2056	Ciltacabtagene Autoleucel, Up To 100 million Autologous B-Cell Maturation	JW - Drug Amount Discarded/Not Admin to Any Patient	10/01/2022
Q2056	Ciltacabtagene Autoleucel, Up To 100 million Autologous B-Cell Maturation	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Q5101	Injection, Filgrastim-SNDZ, Biosimilar, (ZARXIO), 1 mg	JW - Drug Amt Discarded/Not Admin to Any Pati	03/01/2022
Q5110	Injection, Filgrastim-AAFI, Biosimilar, (NIVESTYM), 1 microgram	JW - Drug Amt Discarded/No	05/01/2023
Q5111	Injection, Pegfilgrastim-CBQV (Udenyca), Biosimilar, (Udenyca), 0.5 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Q5114	Injection, Trastuzumab-DKST, Biosimilar, (OGIVRI), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
Q5115	Injection, RITUXIMAB-ABBS, Biosimilar, (TRUXIMA), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	01/01/2023
Q5115*	Injection, RITUXIMAB-ABBS, Biosimilar, (TRUXIMA), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
Q5119	Injection, Rituximab-PVVR, Biosimilar, (RUXIENCE), 10 mg	JZ - Zero Drug Amount Discarded/Not Administered	07/01/2023
V5014	Repair/Modification of A Hearing Aid	LT - Identifies Left Side	01/01/2023
V5014	Repair/Modification of A Hearing Aid	RT - Identifies Right Side	01/01/2023

Note: Q5115 Date for 07/01/2023 is for Reference Screen RF121

Place of Service (POS)

Effective for dates listed the following POS have been added to the codes.

Code	Description	Place of Service	Effective Begin Date
Couc	Bescription	23 - Emergency Room -	Degin Dute
15853	Removal Of Sutures or Staples	Hospital	01/01/2023
	Removal Of Polyps or Growths of Esophagus,		
	Stomach, and/or Upper Small Bowel Using a		
43250	Flexible Endoscope with Electrical Cautery	11 - Office	01/01/2023
	Removal Of Polyps or Growths of Esophagus,		, , , , ,
	Stomach, and/or Upper Small Bowel Using an		
43251	Endoscope with Mechanical Snare	11 - Office	01/01/2023
82575	Creatinine; Clearance	11 – Office	07/01/2022
83037	Hemoglobin A1C Level, by Device for Home Use	12 – Home	01/01/2023
	_		
84154	PSA (Prostate Specific Antigen) Measurement, Free	11 – Office	01/01/2023
91299	Other Diagnostic Procedure for Gastrointestine	11 - Office	07/01/2022
91299	Other Diagnostic Procedure for dastrollitestille		07/01/2022
96156	Assessment Of Health Behavior	23 - Emergency Room -	01/01/2023
90130		Hospital	01/01/2023
	Telephone, Internet, Or Electronic Health Record		
	Assessment and Management with Verbal and		
99446	Written Report by Consulting Physician, 5-10 Minutes	21 - Inpatient Hospital	01/01/2023
33440	Telephone Or Internet Assessment with Verbal and	21 - Inpatient Hospital	01/01/2023
	Written Report by Consulting Physician, 11-20		
99447	Minutes	21 - Inpatient Hospital	01/01/2023
33447	Telephone Or Internet Assessment with Verbal and	21 - Ilipatient Hospital	01/01/2023
	Written Report by Consulting Physician, 21-30		
99448	Minutes	21 - Inpatient Hospital	01/01/2023
33440		21 - Ilipatient Hospital	01/01/2023
	Telephone Or Internet Assessment with Verbal and Written Report by Consulting Physician, More Than		
9449	30 Minutes	21 - Inpatient Hospital	01/01/2023
3443	30 Minutes	ZI impatient nospital	01/01/2023
J0225	Injection, Vutrisiran, 1 mg	12 – Home	01/01/2023

Prior Authorization

Code	Description	Prior Authorization	Effective Begin Date
0121A	Administration Of Coronavirus Vaccine 13, Reserved	04 - PA Not Required for Acute or LTC	04/18/2023
0141A	Administration Of Coronavirus Vaccine 15, Reserved	04 - PA Not Required for Acute or LTC	04/18/2023
0142A	Administration Of Coronavirus Vaccine 15, Reserved	04 - PA Not Required for Acute or LT	04/18/2023
0151A	Administration Of Coronavirus Vaccine 16, Reserved	04 - PA Not Required for Acute or LTC	04/18/2023
T2038	Community Transition, Waiver; Per Service	03 - PA Req'd for Both Acute & LTC	07/01/2023

Provider Type

0.1.	2	Don't Low Town	Effective	5.15.1.
Code	Description	Provider Type	Begin Date	End Date
35721	Exploration (Not Followed by Surgical Repair)	18 – Physician's Assistant		12/31/2022
37799	Other Procedure on Blood Vessel	18 – Physician's Assistant		12/31/2022
4275F	Hepatitis B Vaccine Injection Administered or Previously	19 - Registered Nurse Practitioner		12/31/2022
46220	Removal Of Single External Noncancer Growth of Anus	19 - Registered Nurse Practitioner	12/01/2022	
96004	Physician Review of Gait Analysis Test	14 - Physical Therapist	01/01/2023	
96377	Application Of On-Body Injector for Under Skin Injection	18 – Physician's Assistant	07/01/2022	
96377	Application Of On-Body Injector for Under Skin Injection	19 - Registered Nurse Practitioner	07/01/2022	
A4265	Paraffin, Per Pound	19 - Registered Nurse Practitioner		12/31/2022
J2506	Injection, Pegfilgrastim, Excludes Biosimilar, 0.5 mg	18 – Physician's Assistant	07/01/2022	
J2506	Injection, Pegfilgrastim, Excludes Biosimilar, 0.5 mg	19 - Registered Nurse Practitioner	07/01/2022	
J3489	Injection, Zoledronic Acid, 1 mg	18 – Physician's Assistant	12/01/2022	
J9271	Injection, Pembrolizumab, 1 mg	18 – Physician's Assistant	09/01/2022	
J9316	Injection, Pertuzumab, Trastuzumab, And Hyaluronidase-ZZXF, Per 10 mg	18 – Physician's Assistant	07/01/2022	
J9316	Injection, Pertuzumab, Trastuzumab, And Hyaluronidase-ZZXF, PER 10 mg	19 - Registered Nurse Practitioner	07/01/2022	

Reference Screen 113

The field "Ordering/Referring Provider" has been changed to "N" for the following CPT codes.

97153	Adaptive Behavior Treatment by Technician Using an Established Plan, Each 15 Minutes
97154	Adaptive Behavior Treatment by Technician with Multiple Patients Using an Established Plan, Each 15 Minutes
97155	Adaptive Behavior Treatment by Professional Using an Established Plan, Each 15 Minutes
97156	Adaptive Behavior Treatment by Professional with Family Using an Established Plan, Each 15 Minutes

Revision A4225

Limit 1: is not 10 and Frequency is 1 M

Revenue Codes

- The Revenue Code 0913 (Pstay/Night Care) for Bill Type 131 (HOSP, OP, ADMT THRU DISCH) on RF774 has changed to an "R" with an effective date of October 1, 2008, to show a HCPCS code is Required.
- Effective for the dates listed, the revenue codes have been added to the listed codes.

Code	Description	Revenue Code	Effective Begin Date
0054T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance	0360 - OR Services	07/01/2022
0054T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance	0361 - OR/Minor	07/01/2022
94625	Professional Services for Outpatient Pulmonary Rehabilitation, Per Session	0410 - Respiratory SVC	01/01/2023